Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

Delaet Ingrid

Cooke Julie

Onyia Jude

Research-driven thematic investor & swing trader. Not financial advice

Subscribe: https://t.co/tRfuPuBAXn

Venu

Stock  Market Aficionado & O'Neil CANSLIM Disciple since 1988.  Swing trader and   trend follower.  https://t.co/hRcclQ92kc

Roy Mattox

Investor's Business Daily is guiding investors of all experience levels through the stock market using time-tested strategies and actionable insights.

Investors.com

CEO of The Tribeca Trade Group (TTG) Ex BAML Director ETF & D1 Trading. Momentum & Trend Trader. My MO: stay 1 step ahead of trends & momentum for TTG members

Christian Fromhertz ??

Hybrid Position/Swing Trader, Cancer Survivor, Father, Brother, Uncle, Wine lover and Windsurfer. All opinions are my own and not investment advice.

Neurocrine Biosciences Inc (NBIX) Stock Price, Analysis & Trade Signals